By Mill Chart
Last update: Sep 13, 2025
In the world of long-term investing, few strategies have shown as much staying power as the growth at a reasonable price (GARP) method made popular by legendary fund manager Peter Lynch. His system focuses on finding companies with sustainable earnings growth, good financial health, and valuations that do not assume excessive future expectations. This balanced method lets investors take part in corporate growth while keeping a margin of safety through sensible valuation measures.
Company Overview and Industry Position
INMODE LTD (NASDAQ:INMD) works in the medical aesthetics field, creating and making minimally-invasive aesthetic medical products that use radio frequency technology. The company has built a specific place in face and body contouring, medical aesthetics, and women's health solutions. This position in an increasing healthcare area gives the company exposure to demographic trends that favor aesthetic treatments while keeping a medical technology base that makes barriers to entry for others.
Financial Health and Profitability Metrics
The company's financial numbers match strongly with Lynch's standards for investment selection. Several important indicators are notable:
These numbers show the financial discipline Lynch appreciated, companies that produce large returns without too much borrowing while keeping plenty of liquidity to handle economic downturns.
Valuation and Growth Considerations
InMode offers an interesting valuation case that fits with the GARP philosophy. The company trades at a P/E ratio of 7.8, which seems very low next to both industry peers and the wider market. More importantly, the PEG ratio of 0.34, calculated using the company's five-year EPS growth rate of 23%, points to major undervaluation relative to growth prospects. Lynch specifically looked for companies with PEG ratios under 1.0, thinking they represented the ideal area of growth available at sensible prices.
While recent quarterly results show some growth slowing, the long-term path stays notable. The company has reached 20.4% average yearly revenue growth over the past five years, showing its ability to grow in a competitive market. This maintainable growth speed, neither too slow nor too fast, matches Lynch's liking for companies growing at manageable rates that can be kept up over long periods.
Fundamental Analysis Summary
The full fundamental analysis gives InMode a rating of 7 out of 10, pointing out several strengths that fit with quality investment standards. The company scores very well on profitability and health measures, standing with the top performers in the healthcare equipment industry. Its valuation seems especially interesting, with several metrics indicating the stock trades at a discount to both industry peers and wider market averages.
The analysis does mention some worries about growth slowing in recent times, which investors should watch closely. However, the mix of good financial health, notable profitability, and sensible valuation makes an interesting profile for investors looking for companies that meet quality growth standards without paying high prices.
Investment Considerations and Further Research
For investors wanting to look into similar opportunities, other companies meeting Peter Lynch's investment standards can be found using our specialized stock screener. This tool lets investors find companies with similar traits, strong growth, sensible valuations, and solid financial bases.
As with any investment method, the Lynch system works best as part of a varied portfolio plan. While InMode shows many traits Lynch liked, investors should do their own full research and think about their personal risk tolerance and investment goals before making any investment decisions.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or recommendation to buy or sell any securities. The information presented should not be construed as an endorsement of any particular investment strategy. Readers should conduct their own research and consult with a qualified financial advisor before making investment decisions.
NASDAQ:INMD (9/16/2025, 10:58:33 AM)
14.845
-0.01 (-0.1%)
Find more stocks in the Stock Screener